Pathkind Diagnostics is all set to transform diabetes care in India with Roche Diagnostics’ cardiac biomarker- NTProBNP that is used in the management of Type 2 Diabetes (T2DM). NTProBNP is the biomarker for detecting heart failure in patients and Roche Diagnostics have received a claim extension allowing it to be used for identification of the risk of heart failure and other cardiovascular risks in people living with T2DM. With the incorporation of NTProBNP in diabetes management, Pathkind aims to provide diabetes and cardiac care.
Sanjeev Vashishta, MD & CEO Pathkind Labs said, “Diabetes patients must receive a prompt diagnosis of heart disease in order to manage their health to the best of their ability. The co-existence of diabetes mellitus and heart failure has significant clinical and economic implications in terms of clinical visits, hospital admissions, quality of life, morbidity, and mortality. The addition of this high-sensitivity NTProBNP test will assist healthcare professionals and patients in making important medical decisions.”
Narendra Varde, Managing Director, Roche Diagnostics India & Neighboring Markets said “Today, modern technology and our evolving understanding of disease have given us newer options for personalising therapy, reducing unnecessary expenses, and protecting those in need. Incorporating NTProBNP, a simple blood test, to help detect and monitor heart failure as part of diabetes treatment and management is critical and essential. In order to lower mortality and CVD events, it is crucial to screen people with T2DM for CVD risk, therefore our partnership with Pathkind will be a turning point in diabetes management.”
According to Dr Aarti Khanna Nagpal, Pathkind Labs, “In diabetic heart failure patients, the value of NTProBNP holds a pivotal role in the evaluation of their overall status, facilitating the establishment of correct therapy management and follow-up. Evidence gathered so far highlights that NTProBNP is a direct predictor of adverse outcome and cardiovascular mortality, making this marker instrumental in the management of CVDs in T2D patients. With diabetes’ unrelenting growth, it is paramount for healthcare professionals to re-evaluate how they treat and manage a challenging patient population.”
